

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2024 (12.09.2024)



(10) International Publication Number
WO 2024/186927 A3

- (51) International Patent Classification:
C07K 16/10 (2006.01) C07K 16/42 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2024/018727

(22) International Filing Date:
06 March 2024 (06.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/489,373 09 March 2023 (09.03.2023) US
63/620,111 11 January 2024 (11.01.2024) US

(71) Applicant: KITE PHARMA, INC. [US/US]; 2400 Broad-
way, Santa Monica, California 90404 (US).

(72) Inventors: COON, Michael E.; Kite Pharma, Inc., c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal-
ifornia 94404 (US). CORTESIO, Christa; Kite Pharma,
Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster

City, California 94404 (US). SIEVERS, Stuart A.; 15467
Lemay Street, Van Nuys, California 91406 (US).

(74) Agent: SANNY, Tony et al.; Kite Pharma, Inc., c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ANTIGEN BINDING MOLECULES AND METHODS OF USE




Figure 8

(57) Abstract: The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

24 October 2024 (24.10.2024)